Gilman Hill Asset Management LLC Raises Stock Holdings in Bristol-Myers Squibb Co (NYSE:BMY)

Gilman Hill Asset Management LLC increased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 144.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,989 shares of the biopharmaceutical company’s stock after purchasing an additional 20,064 shares during the period. Gilman Hill Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $2,182,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. BTR Capital Management Inc. boosted its holdings in Bristol-Myers Squibb by 31.1% in the fourth quarter. BTR Capital Management Inc. now owns 5,265 shares of the biopharmaceutical company’s stock worth $338,000 after acquiring an additional 1,250 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Bristol-Myers Squibb by 113.2% during the fourth quarter. IFP Advisors Inc now owns 44,715 shares of the biopharmaceutical company’s stock valued at $2,858,000 after purchasing an additional 23,744 shares in the last quarter. Zeke Capital Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 146.8% during the fourth quarter. Zeke Capital Advisors LLC now owns 18,557 shares of the biopharmaceutical company’s stock valued at $1,191,000 after purchasing an additional 11,038 shares in the last quarter. Comprehensive Portfolio Management LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $235,000. Finally, Bell & Brown Wealth Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 91.3% during the fourth quarter. Bell & Brown Wealth Advisors LLC now owns 41,330 shares of the biopharmaceutical company’s stock valued at $2,753,000 after purchasing an additional 19,728 shares in the last quarter. 83.02% of the stock is currently owned by institutional investors.

BMY stock traded up $0.17 during trading on Friday, reaching $66.95. The stock had a trading volume of 1,857,084 shares, compared to its average volume of 15,257,604. Bristol-Myers Squibb Co has a 52 week low of $42.48 and a 52 week high of $67.09. The stock’s 50 day moving average is $62.71 and its two-hundred day moving average is $53.14. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. The firm has a market cap of $108.25 billion, a PE ratio of 16.82, a PEG ratio of 0.85 and a beta of 0.73.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.11. The business had revenue of $6.01 billion during the quarter, compared to analysts’ expectations of $5.89 billion. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. The business’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.09 earnings per share. On average, research analysts anticipate that Bristol-Myers Squibb Co will post 4.47 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be given a $0.45 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. The ex-dividend date is Thursday, January 2nd. This represents a $1.80 dividend on an annualized basis and a yield of 2.69%. Bristol-Myers Squibb’s dividend payout ratio is presently 45.23%.

BMY has been the topic of a number of research analyst reports. Bank of America initiated coverage on Bristol-Myers Squibb in a report on Wednesday, October 16th. They set a “buy” rating and a $60.00 price target on the stock. Mizuho began coverage on Bristol-Myers Squibb in a report on Monday, November 25th. They issued a “buy” rating on the stock. Citigroup raised Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 target price on the stock in a report on Monday, January 6th. Wolfe Research set a $66.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a report on Friday, November 1st. Finally, Gabelli began coverage on Bristol-Myers Squibb in a report on Wednesday, November 27th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $61.69.

In other Bristol-Myers Squibb news, SVP John E. Elicker sold 15,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total value of $849,900.00. Following the completion of the sale, the senior vice president now owns 74,471 shares in the company, valued at $4,219,526.86. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Louis S. Schmukler sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total value of $1,414,000.00. Following the completion of the sale, the insider now owns 31,963 shares of the company’s stock, valued at approximately $1,807,827.28. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Support Level

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.